α-Synuclein expression in HEK293 cells enhances the mitochondrial sensitivity to rotenone

Neuroscience Letters

Volumn 351, Issue 1, 2003, Pages 29-32

  Orth, M ^a,b   Tabrizi, S J ^a,b   Schapira, A H V ^a,b   Cooper, J M ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cell culture; Complex I; Mitochondria; Mitochondrial membrane potential; Parkinson's disease; Rotenone; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; MUTANT PROTEIN; ROTENONE;

ARTICLE; CELL FUNCTION; CELL LINE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EMBRYO; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; KIDNEY CELL; LEWY BODY; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; WILD TYPE;

EID: 0141671773     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(03)00941-8     Document Type: Article

References (19)

1. Berridge M.V., Tan A.S. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch. Biochem. Biophys. 303:1993;474-482.
2. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3:2000;1301-1306.
3. Dauer W., Kholodilov N., Vila M., Trillat A.C., Goodchild R., Larsen K.E., Staal R., Tieu K., Schmitz Y., Yuan C.A., Rocha M., Jackson-Lewis V., Hersch S., Sulzer D., Przedborski S., Burke R., Hen R. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. USA. 99:2002;14524-14529.
4. Gu M., Cooper J.M., Taanman J.W., Schapira A.H. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann. Neurol. 44:1998;177-186.
5. Hsu L.J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M., Wong J., Takenouchi T., Hashimoto M., Masliah E. alpha-Synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157:2000;401-410.
6. Krige D., Carroll M.T., Cooper J.M., Marsden C.D., Schapira A.H. Platelet mitochondrial function in Parkinson's disease. Ann. Neurol. 32:1992;782-788.
7. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
8. Lee H.J., Shin S.Y., Choi C., Lee Y.H., Lee S.J. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J. Biol. Chem. 277:2002;5411-5417.
9. Lehmensiek V., Tan E.M., Schwarz J., Storch A. Expression of mutant alpha-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro. NeuroReport. 13:2002;1279-1283.
10. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 287:2000;1265-1269.
11. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22:1999;123-144.
12. Orth M., Schapira A.H. Mitochondrial involvement in Parkinson's disease. Neurochem. Int. 40:2002;533-541.
13. Parker W.D. Jr., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26:1989;719-723.
14. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
15. Rickwood D., Hayes A. An evaluation of methods used to prepare yeast mitochondria for transcriptional studies. Prep. Biochem. 14:1984;163-171.
16. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54:1990;823-827.
17. Sherer T.B., Betarbet R., Stout A.K., Lund S., Baptista M., Panov A.V., Cookson M.R., Greenamyre J.T. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 22:2002;7006-7015.
18. Tabrizi S.J., Orth M., Wilkinson J.M., Taanman J.W., Warner T.T., Cooper J.M., Schapira A.H. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum. Mol. Genet. 9:2000;2683-2689.
19. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., Sawa A., Dawson V.L., Dawson T.M., Ross C.A. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10:2001;919-926.